目的 探讨异位胰腺的临床特点。方法 回顾性分析解放军第306医院1996年10月至2004年12月收治的11例异位胰腺患者的临床资料。结果 异位胰腺组织位于胃小弯1例,胃窦3例,空肠2例,回肠2例,胆囊壁1例,肝左外叶胆管壁1例,胆总管壁1例。表现为间歇性下消化道出血2例,因反复腹痛、发热,行钡餐检查发现空肠憩室而诊断为空肠憩室炎1例,胆囊息肉样病变、急性胆囊炎伴胆源性胰腺炎1例,肝胆管结石并反复急性胆管炎1例,胆总管占位性病变1例,余5例无明显症状和体征。11例术前均未考虑异位胰腺,其中10例为腹部手术偶然发现, 1例为胃镜活检证实。11例异位胰腺均单发,直径为0.5~1.8 cm。结论 异位胰腺虽然少见,在胃肠道和胆道疾病的鉴别诊断中对该病应予重视。
Objective To explore the association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and breast cancer risk and to investigate the interaction with menopausal status by meta-analysis. Methods Such databases as The Cochrane Libtary (Issue1, 2010), Pubmed, CBM, CNKI and WanFang Data were searched from the date of their establishment to October, 2010, and the case-control studies of MnSOD Val-9Ala polymorphism and breast cancer risk were collected according to the inclusion and exclusion criteria. Then the quality of the included trials was assessed and meta-analysis was performed by RevMan 4.2.10 software. Results A total of 14 studies involving 17 842 patients were included. The results of meta-analyses showed no significant relation between MnSOD Val-9Ala polymorphism and the breast cancer susceptibility (Val/Ala vs. Val/Val: OR=1.04, 95%CI 0.93 to 1.17; Ala/Ala vs. Val/Val: OR=1.12, 95%CI 0.95 to 1.33; Ala/Ala vs. Val/Ala+Val/Val: OR=1.06, 95%CI 0.93 to 1.20; Val/Ala+ Ala/Ala vs. Val/Val: OR=1.06, 95%CI 0.94 to 1.10). However, in the subgroup analysis, the breast cancer risk significantly increased for premenopausal women (Val/Ala+Ala/Ala vs. Val/Val: OR=1.15, 95%CI 1.01 to1.31). Conclusion This meta-analysis suggests that the MnSOD Val-9Ala polymorphism is not significantly associated with the breast cancer susceptibility, but it may increase the risk of breast cancer in the presence of menopausal state.